Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Multimodal Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04917770Phase 2Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of sintilimab in nasopharyngeal carcinoma (NPC), sponsored by West China Hospital of Sichuan University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04917770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917770.